Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

<i>Background and Objectives</i>: In recent years, the effectiveness of chemotherapy after immune checkpoint inhibitor administration has attracted attention in various cancers, including head and neck cancers. However, individual assessments of the administered chemotherapy regimens are insufficien...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Shinsuke Suzuki, Satoshi Toyoma, Yohei Kawasaki, Koh Koizumi, Nobuko Iikawa, Kazuhiro Shiina, Tentaro Endo, Tomoe Abe, Teppei Kouga, Takechiyo Yamada
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2021-10-01
Serie:	Medicina
Soggetti:	head and neck squamous cell carcinoma cetuximab paclitaxel immune checkpoint inhibitor chemotherapy
Accesso online:	https://www.mdpi.com/1648-9144/57/11/1151
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!